• Tariq Pervez


Ovarian cancer is very important malignancy of woman as far as its incidence and mortality is concerned. Although majority presents at late stage but still there is a reasonable response to currently available chemotherapy drugs and their use in multimodality setting. Besides good response to chemotherapy drugs, majority have recurrence. So there is a need for new drugs, new trends and their combinations. All these issues will be discussed in this review article


Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;127:73-9.

Ries LAG, Eisner MP, Kosary CL. SEER Cancer Statistics Review, 1973-1999. Bethesda, Md: National Cancer Institute; 2002.

Parvez T. Prevalence of Cancer in Different Hospitals of Lahore (Retrospective study). The Cancer Research 1992;1(2):6-13.

Brose MS, Rebbeck TR, Calzone KA. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.

Piccart M, Bertelsen K, Stuart G. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin (TP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer (AOC). Ann Oncol 2002;13:109.

McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.

Berek JS, Bertelsen K, du Bois A. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 1999;10(suppl 1):87-92.

Schink JC, Weller E, Harris LS. Outpatient Taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group phase II study (E2E93). Cancer J 2001;7:155-64.

Vasey PA. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002;21:202a.

International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.

Rothenberg ML, Liu PY, Wilczynski S. Excellent 2-year survival in women with optimally-debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: a SWOG-ECOG-NCIC study (S9619). Proc Am Soc Clin Oncol 2002;21:203a.

Alberts DS, Markman M, Armstrong D. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J Clin Oncol 2002;20:3944-6.

Markman M, Liu PY, Wilczynski S, Monk BJ, Copeland L, Alberts D. Phase 3 randomized trial of 12 vs. 3 months of single agent paclitaxel in patients with advanced ovarian cancer who attained a clinically-defined complete response to platinum/paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group study. Gynecol Oncol 2002;84:479.

Kristensen G, Vergote I, Stuart G. First line treatment of ovarian cancer FIGO stages IIB-IV with paclitaxel/ epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC): interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol 2002;21:202a.

Gibbs DD, Pyle L, Allen M. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer 2002;86:1379-84.

Gordon AN, Asmar L, Messing M. Phase II study of sequential topotecan HCI (T) in combination with carboplatin (C) followed by paclitaxel (P) via three-hour infusion in combination with carboplatin (C) in the treatment of newly diagnosed ovarian cancer (OvCa) patients (pts) with advanced disease. Proc Am Soc Clin Oncol 2002;21:213a.

Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Sixth Edition. Philadelphia, Pa: Lippincott Williams & Wilkins;2001:1597-632.

Rose PG, Blessing JA, Mayer AR. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-10.

Shapiro JD, Millward MJ, Rischin D. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.

Gordon AN, Fleagle JT, Guthrie D. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.

Trimble EL, Adams JD, Vena D. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J Clin Oncol 1993;11:2405-10.

Goldberg JM, Piver MS, Hempling RE. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1996;63:312-7.

Guastalla JP, Pujade-Lauraine E, Weber B. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann Oncol 1998;9:37-43.

Hatch KD, Beecham JB, Blessing JA. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991;68:269-71.

ten Bokkel Huinink W, Gore M, Carmichael J. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.

Gore M, ten Bokkel Huinink W, Carmichael J. Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. J Clin Oncol 2001;19:1893-1900.

O'Byrne KJ, Bliss P, Graham JD. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002;21:203a.

van der Burg MEL, van Lent M, Buyse M. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-34.

Ehlen TG, Gordon AN, Fingert HJ. Adjuvant treatment with monoclonal antibody, OvaRex MAb-B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse (TTR) in a randomized, placebo-controlled study in patients (pts) with advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002;21:9a.

Wagner U, Kohler S, Reinartz S. Consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001;7:1154-62.

Garcia A, Gordon A, Markman M. Phase I/II trial of IM862, a novel immunomodulator with anti-angiogenic activity, in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 2001;20:211a.

Finn RS, Beryt M, Konecny G. ZD1839 ('Iressa') acts synergistically with chemotherapy in ovarian cancer cells expressing high levels of the epidermal growth factor receptor. Proc Am Soc Clin Oncol 2002;21:29b.

Finkler N, Gordon A, Crozier M. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 2001;20:208a.